383 related articles for article (PubMed ID: 35447476)
1. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
[TBL] [Abstract][Full Text] [Related]
2. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
[TBL] [Abstract][Full Text] [Related]
3. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
4. Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing.
Corace K; Suschinsky K; Wyman J; Leece P; Cragg S; Konefal S; Pana P; Barrass S; Porath A; Hutton B
Int J Drug Policy; 2022 Apr; 102():103573. PubMed ID: 35123246
[TBL] [Abstract][Full Text] [Related]
5. Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis.
Garg R; Kitchen SA; Men S; Campbell TJ; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
Drug Alcohol Depend; 2022 Jul; 236():109459. PubMed ID: 35489179
[TBL] [Abstract][Full Text] [Related]
6. A population-based time-series analysis of opioid agonist treatment dispensed during pregnancy.
Schmidt RA; Everett K; Perez-Brumer A; Strike C; Rush B; Gomes T
Addiction; 2024 Jun; 119(6):1111-1122. PubMed ID: 38476027
[TBL] [Abstract][Full Text] [Related]
7. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
[TBL] [Abstract][Full Text] [Related]
8. Impact of changes to the delivery of opioid agonist treatment, introduced during the COVID-19 pandemic, on treatment access and dropout in Ireland: An interrupted time series analysis.
Durand L; Boland F; Harnedy N; Delargy Í; Scully M; Bourke M; Ebbitt W; Otero Vázquez M; Keenan E; Cousins G
J Subst Use Addict Treat; 2023 Jun; 149():209029. PubMed ID: 37003538
[TBL] [Abstract][Full Text] [Related]
9. Changes in Opioid Agonist Treatment Practice in Germany during the COVID-19 Pandemic: What Have Physicians Done, and What Would They Like to Keep Doing?
Lehmann K; Kuhn S; Schulte B; Verthein U
Eur Addict Res; 2023; 29(5):323-332. PubMed ID: 37557092
[TBL] [Abstract][Full Text] [Related]
10. Deimplementation in the provision of opioid agonist treatment to achieve equity of care for people engaged in treatment: a qualitative study.
Conway A; Marshall AD; Crawford S; Hayllar J; Grebely J; Treloar C
Implement Sci; 2023 Jun; 18(1):22. PubMed ID: 37296448
[TBL] [Abstract][Full Text] [Related]
11. Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy.
Moallef S; DeBeck K; Fairbairn N; Cui Z; Brar R; Wilson D; Johnson C; Milloy MJ; Hayashi K
Addict Sci Clin Pract; 2022 Dec; 17(1):73. PubMed ID: 36522789
[TBL] [Abstract][Full Text] [Related]
12. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
[TBL] [Abstract][Full Text] [Related]
13. Opioid agonist treatment uptake within provincial correctional facilities in British Columbia, Canada.
Kurz M; Dale LM; Min JE; Hongdilokkul N; Greiner L; Olley M; McLeod KE; Slaunwhite A; Nosyk B
Addiction; 2022 May; 117(5):1353-1362. PubMed ID: 34729848
[TBL] [Abstract][Full Text] [Related]
14. Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.
Eugenia Socias M; Choi JC; Fairbairn N; Johnson C; Wilson D; Debeck K; Brar R; Hayashi K
Int J Drug Policy; 2023 Aug; 118():104075. PubMed ID: 37271070
[TBL] [Abstract][Full Text] [Related]
15. Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018.
Krebs E; Homayra F; Min JE; MacDonald S; Gold L; Carter C; Nosyk B
Drug Alcohol Depend; 2021 Aug; 225():108799. PubMed ID: 34087747
[TBL] [Abstract][Full Text] [Related]
16. Comparing Canadian and United States opioid agonist therapy policies.
Priest KC; Gorfinkel L; Klimas J; Jones AA; Fairbairn N; McCarty D
Int J Drug Policy; 2019 Dec; 74():257-265. PubMed ID: 30765118
[TBL] [Abstract][Full Text] [Related]
17. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
18. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.
Oviedo-Joekes E; MacDonald S; Boissonneault C; Harper K
Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):22. PubMed ID: 33673847
[TBL] [Abstract][Full Text] [Related]
19. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
Mocanu V; Bozinoff N; Wood E; Jutras-Aswad D; Le Foll B; Lim R; Cheol Choi J; Yin Mok W; Eugenia Socias M;
Drug Alcohol Depend; 2023 Jul; 248():109932. PubMed ID: 37224674
[TBL] [Abstract][Full Text] [Related]
20. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
